Research

My current research interest is investigating the quality of food offered to children outside of the home which is often of poor nutritional content and provides few options. The number of families choosing to eat out has increased over the last decade resulting in a significant contribution to the weekly dietary intake of children. The nutritional quality of food offered to children outside the home should be examined as currently no UK regulations exist and research is limited within this area. If you are interested in collaborating please get in touch via the contact form.

Publications*

Hieber C, Mustafa AM, Neuroth S, Henninger S, Wollscheid HP, Zabkiewicz J, Lazenby M, Alvares C, Mahboobi S, Butter F, Brenner W, Bros M, Krämer OH. Inhibitors of the tyrosine kinases FMS-like tyrosine kinase-3 and WEE1 induce apoptosis and DNA damage synergistically in acute myeloid leukemia cells. (2024) Biomed Pharmacother. ;177:117076. doi: 10.1016/j.biopha.2024.117076. Epub 2024 Jul 5. PMID: 38971011.

Thomas, M. (2022). A Case Study Examining How Affordable and Accessible the Eatwell Guide is Across Wales. MSc Research Article, University of Chester

Zabkiewicz J, Lazenby M, Edwards G, et al. (2020). Combination of a mitogen-activated protein kinase inhibitor with the tyrosine kinase inhibitor pacritinib combats cell adhesion-based residual disease and prevents re-expansion of FLT3-ITD acute myeloid leukaemia Br J Haematol; 10.1111/bjh.16665. doi:10.1111/bjh.16665

Lazenby, M. (2019). Characterisation of Extracellular Vesicles from the Microenvironment in High-Risk Acute Myeloid Leukaemia. MPhil Thesis, Cardiff University.

Lazenby, M., Ottmann, O. G., Wilson, K., Alvares, C., & Zabkiewicz, J. (2018). Extracellular Microvesicle Cytokines Secreted from Bone Marrow Mesenchymal Cells Mediate Proliferative and Survival Advantage in Acute Myeloid Leukaemia. Blood, 132(Suppl 1), 2744.

Lazenby M, Hills R, Burnett AK, Zabkiewicz J.(2015) The HSP90 inhibitor ganetespib: A potential effective agent for Acute Myeloid Leukemia in combination with cytarabine. Leuk Res.39(6):617-24

Ostronoff F, Othus M, Lazenby M, Estey E, Appelbaum FR, Evans A, Godwin J, Gilkes A, Kopecky KJ, Burnett A, List AF, Fang M, Oehler VG, Petersdorf SH, Pogosova-Agadjanyan EL, Radich JP, Willman CL, Meshinchi S, Stirewalt DL.(2015) Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council report.J Clin Oncol 1;33(10):1157-64

Lazenby M, Gilkes AF, Marrin C, Evans A, Hills RK, Burnett AK (2014) The prognostic relevance of flt3 and npm1 mutations on older patients treated intensively or non-intensively: a study of 1312 patients in the UK NCRI AML16 trial. Leukemia.28(10):1953-9

Walsby E, Lazenby M, Pepper C, Knapper, S, Burnett A (2013) The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells. Br J Haematol. 161(1):57-67

Walsby E, Lazenby M, Pepper C, Burnett A (2011) The cyclin-dependent kinase inhibitor SNS-032 has single agent activity in AML cells and is highly synergistic with cytarabine. Leukemia. 25 (3):411-9

Gale, Rosemary, Hills, Robert Kerrin, Green, Claire, Patel, Yashma, Gilkes, Amanda F., Lazenby, Michelle, Wheatley, Keith, Linch, David C. and Burnett, Alan Kenneth (2008). The impact of FLT3-ITD and NPM1 Mutational Status on the outcome of ATRA therapy in patients with non-APL AML: results of the UK MRC AML12 trial [Abstract]. Blood -New York- 112 (11), p. 207.

Margaret Dellett, Michelle Lazenby, Alan K Burnett, and Ken I Mills (2008) Azacytidine as a Maintenance Therapy in Elderly AML Progressively Demethylates CpG Sites within the p16 Gene
Blood (ASH Annual Meeting Abstracts); 112: 4466.

Lavignac N, Lazenby M, Franchini J, Ferruti P, Duncan R. (2005) Synthesis and preliminary evaluation of poly(amidoamine)-melittin conjugates as endosomolytic polymers and/or potential anticancer therapeutics. Int. J. Pharm. 300 (1-2):102-12

Lavignac N, Lazenby M, Foka P, Malgesini B, Verpilio I, Ferruti P, Duncan R. (2004) Synthesis and endosomolytic properties of poly(amidoamine) block copolymers. Macromol. Biosci. 4 (10):922-9

*Lazenby is maiden name